Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
Ohmoto
Kenji
K
Tsuduki
Masayuki
M
Yamamoto
Shinichiro
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D011241:Prednisone / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects*; D014775:Virus Activation / Q000187:drug effects*
D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone